Experienced in Acute Myelomonocytic Leukemia

Dr. Manish R. Sharma

Oncology | Hematology Oncology
Cancer And Hematology Centers Of Western Mi, P.C.
145 Michigan St Ne, Suite 3100, 
Grand Rapids, MI 
 (1831.7 mi)
Accepting New Patients
Experienced in Acute Myelomonocytic Leukemia
Cancer And Hematology Centers Of Western Mi, P.C.
145 Michigan St Ne, Suite 3100, 
Grand Rapids, MI 
 (1831.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

Manish Sharma is an Oncologist and a Hematologist Oncology provider in Grand Rapids, Michigan. Dr. Sharma and is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Liver Cancer, Ovarian Cancer, Colorectal Cancer, Bone Marrow Transplant, and Nephrectomy. Dr. Sharma is currently accepting new patients.

His clinical research consists of co-authoring 86 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Acute Myelomonocytic Leukemia.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Spectrum Health
Spectrum Health United Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

CANCER AND HEMATOLOGY CENTERS OF WESTERN MI, P.C.
145 Michigan St Ne, Suite 3100, Grand Rapids, MI 49503

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2024
Intervention Type: Biological
Study Drug: MGD019 Bispecific DART Protein Binding PD-1 and CTLA-4
Study Phase: Phase 1
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: April 23, 2024
Intervention Type: Biological
Study Drugs: MGC018, MGA012
Study Phase: Phase 1/Phase 2
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: LY3475070, Pembrolizumab
Study Phase: Phase 1
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drugs: SY-5609, Fulvestrant
Study Phase: Phase 1
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2023
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: PDR001, INC280
Study Phase: Phase 1/Phase 2
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: February 03, 2023
Intervention Type: Drug
Study Phase: Early Phase 1
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-100 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 Via Intravenous Infusion in Patients With Advanced Solid Tumors
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of CPI-200 Via Intravenous Infusion in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 24, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
Enrollment Status: Terminated
Publish Date: June 10, 2021
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma
Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 13, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment
A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment
Enrollment Status: Completed
Publish Date: April 22, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: April 19, 2017
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
View 26 Less Clinical Trials

86 Total Publications

Minimally Modified HIV-1 Infection of Macaques: Development, Utility, and Limitations of Current Models.
Minimally Modified HIV-1 Infection of Macaques: Development, Utility, and Limitations of Current Models.
Journal: Viruses
Published: September 24, 2024
Similar Doctors
Advanced in Acute Myelomonocytic Leukemia
Dr. Brett T. Brinker
Hematology Oncology | Hematology | Oncology
Advanced in Acute Myelomonocytic Leukemia
Dr. Brett T. Brinker
Hematology Oncology | Hematology | Oncology

Cancer And Hematology Centers Of Western Mi, P.C.

145 Michigan St Ne, Suite 3100, 
Grand Rapids, MI 
 (0.1 mi)
616-954-9800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brett Brinker is a Hematologist Oncology specialist and a Hematologist in Grand Rapids, Michigan. Dr. Brinker and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Brinker is currently accepting new patients.

Advanced in Acute Myelomonocytic Leukemia
Dr. Latha S. Polavaram
Hematology Oncology | Hematology | Oncology
Advanced in Acute Myelomonocytic Leukemia
Dr. Latha S. Polavaram
Hematology Oncology | Hematology | Oncology

Cancer And Hematology Centers Of Western Mi, P.C.

12460 Riley St, 
Holland, MI 
 (23.7 mi)
616-399-6500
Languages Spoken:
English, Hindi, Telugu
See accepted insurances
Accepting New Patients

Latha Polavaram is a Hematologist Oncology specialist and a Hematologist in Holland, Michigan. Dr. Polavaram and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Polavaram is currently accepting new patients.

Experienced in Acute Myelomonocytic Leukemia
Dr. Michael H. Zakem
Hematology Oncology | Hematology | Oncology
Experienced in Acute Myelomonocytic Leukemia
Dr. Michael H. Zakem
Hematology Oncology | Hematology | Oncology

Cancer And Hematology Centers Of Western Mi, P.C.

145 Michigan St Ne, Suite 3100, 
Grand Rapids, MI 
 (0.1 mi)
616-954-9800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Zakem is a Hematologist Oncology specialist and a Hematologist in Grand Rapids, Michigan. Dr. Zakem and is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-Hodgkin Lymphoma, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Zakem is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile